Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Kun Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2513-768X; OpenAlex author ID A5100366717. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 3 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: 3 papers

Papers 20

  1. Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage. Co-author DOI 10.1002/jat.4494↗
  2. An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer. Co-author DOI 10.1007/s00259-023-06115-5↗
  3. Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a retrospective analysis for prognostic fac… Co-author DOI 10.1080/02656736.2023.2278417↗
  4. Deep learning radiomics of dual-energy computed tomography for predicting lymph node metastases of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00259-021-05573-z↗
  5. Involvement of elevated ASF1B in the poor prognosis and tumorigenesis in pancreatic cancer. Co-author DOI 10.1007/s11010-022-04404-5↗
  6. Deep learning radiomics based on contrast-enhanced ultrasound images for assisted diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis. Co-author DOI 10.1186/s12916-022-02258-8↗
  7. Construction of a novel bispecific fusion protein to enhance targeting for pancreatic cancer imaging. Co-author DOI 10.1016/j.biomaterials.2020.120161↗
  8. Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis. First author DOI 10.1177/1559325820942065↗
  9. An Innovation for Treating Orthotopic Pancreatic Cancer by Preoperative Screening and Imaging-Guided Surgery. Co-author DOI 10.1007/s11307-018-1209-8↗
  10. A novel plectin/integrin-targeted bispecific molecular probe for magnetic resonance/near-infrared imaging of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2018.08.048↗
  11. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Co-author DOI 10.1016/j.pan.2017.08.072↗
  12. Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine. First author PMID 27073725↗
  13. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. Co-author PMID 27448780↗
  14. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0096177↗
  15. Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer. Co-author DOI 10.1159/000348530↗
  16. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1371/journal.pone.0060529↗
  17. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. First author DOI 10.5754/hge13498↗
  18. High intensity focused ultrasound treatment for patients with advanced pancreatic cancer: a preliminary dosimetric analysis. Co-author DOI 10.3109/02656736.2012.713541↗
  19. Metastatic adenocarcinoma of the epididymis from pancreatic cancer successfully treated by chemotherapy and high-intensity focused ultrasound therapy: a case r… Co-author DOI 10.1097/mpa.0b013e318221816d↗
  20. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Co-author DOI 10.3109/02656736.2010.525588↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jie Tian · 6 shared papers, 2018–2023 · strength 0.74
  2. Zhiqiang Meng · 7 shared papers, 2011–2023 · strength 0.47
  3. Xiangdong Hua · 2 shared papers, 2022–2023 · strength 0.40
  4. Xinming Zhao · 2 shared papers, 2020–2023 · strength 0.30
  5. Tong Tong · 2 shared papers, 2022 · strength 0.27
  6. Zhen Chen · 7 shared papers, 2011–2017 · strength 0.27
  7. Chien‐shan Cheng · 2 shared papers, 2016–2023 · strength 0.27
  8. Huili Zhu · 2 shared papers, 2013–2023 · strength 0.26
  9. Ailing Zhong · 1 shared paper, 2023 · strength 0.22
  10. Shu Dong Ma · 1 shared paper, 2023 · strength 0.22
  11. Siyuan Li · 1 shared paper, 2023 · strength 0.22
  12. Peng Wang · 5 shared papers, 2011–2017 · strength 0.20
  13. Qian Wang · 2 shared papers, 2018–2020 · strength 0.19
  14. Zihua Wang · 2 shared papers, 2018–2020 · strength 0.19
  15. Seok Hyun Yun · 1 shared paper, 2023 · strength 0.18
  16. Qian Wang · 1 shared paper, 2023 · strength 0.18
  17. Jionghui Gu · 1 shared paper, 2022 · strength 0.14
  18. Tianan Jiang · 1 shared paper, 2022 · strength 0.14
  19. Ling Song · 1 shared paper, 2022 · strength 0.14
  20. Shuiqing Zhuo · 1 shared paper, 2022 · strength 0.13
  21. Chao An · 1 shared paper, 2022 · strength 0.13
  22. Lizhi Liu · 1 shared paper, 2022 · strength 0.13
  23. Tao Wu · 1 shared paper, 2020 · strength 0.12
  24. Bo Tang · 1 shared paper, 2020 · strength 0.12
  25. Wen Fu · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.